Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
about
Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX.Autoantibody response to a novel tumor-associated antigen p90/CIP2A in breast cancer immunodiagnosis.Alpha 1-antitrypsin: a novel tumor-associated antigen identified in patients with early-stage breast cancer.Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer.Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer.The Impact of Sample Storage Time on Estimates of Association in Biomarker Discovery Studies.Elevated Levels of Serum Tumor Markers CEA and CA15-3 Are Prognostic Parameters for Different Molecular Subtypes of Breast CancerMultiplexed detection of serological cancer markers with plasmon-enhanced Raman spectro-immunoassay.Gene expression of circulating tumour cells and its correlation with tumour stage in breast cancer patients.Activated Leukocyte Cell Adhesion Molecule (ALCAM) in Saudi Breast Cancer Patients as Prognostic and Predictive Indicator.Nomograms for Predicting the Prognostic Value of Pre-Therapeutic CA15-3 and CEA Serum Levels in TNBC Patients.Use of CEA and CA15-3 to Predict Axillary Lymph Node Metastasis in Patients with Breast CancerA clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy.Assessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen (CEA) Levels in Breast Cancer Patients: A Meta-AnalysisA clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease.Usefulness of traditional serum biomarkers for management of breast cancer patients.Prognostic Impact of the Tumor Marker CA 15-3 in Patients With Breast Cancer and Bone Metastases Treated With Palliative Radiotherapy.Preoperative Serum Carcinoembryonic Antigen as a Marker for Predicting the Outcome of Three Cancers.Can IgA, C3, IL-6 and TNF-α act as predictors for reoccurrence of breast cancer among Iraqi women?Preoperative serum tissue polypeptide-specific antigen is a valuable prognostic marker in breast cancer.Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer.Serum microRNA-195 is down-regulated in breast cancer: a potential marker for the diagnosis of breast cancer.Serum CA125 is a predictive marker for breast cancer outcomes and correlates with molecular subtypes.Expression of androgen receptors in primary breast cancer.Serial determination of CEA and CA 15.3 in breast cancer follow-up: an assessment of their diagnostic accuracy for the detection of tumour recurrences.Plasma TuM2-PK correlates with tumor size, CRP and CA 15-3 in metastatic breast carcinomas; short versus long term follow up study of the Egyptian breast cancer patients.Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.Prognostic role of CA15.3 in 7942 patients with operable breast cancer.CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients.CA 15-3 serum levels in patients with ductal breast carcinoma: relationship with clinicopathological parameters and tumor markers.Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients.Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkersLymph node metastasis and high serum CEA are important prognostic factors in hormone receptor positive and HER2 negative breast cancer
P2860
Q33830752-C6FBEDAB-4B3C-4928-BBC0-5988D2805F61Q33895872-52954840-AC5E-4585-8E2A-49C7056A88D4Q34347517-0178A347-8ADC-493B-B003-F6DBAD604371Q34607218-4D962BDC-178C-426F-90E0-21ECAC10B5BEQ34646288-4C160480-7913-4432-A9FA-B286148B17D1Q35090470-F1A097AB-B1F6-44DA-AD3F-2B69E022F2BDQ35711186-099D662A-0B00-4B3F-92A0-E7E142129452Q35787480-AA6EED84-0E39-470F-A8E1-D655C1FEE09CQ35959805-6D67AE5C-C3A5-422C-89D9-972AC2D9F1F5Q36089828-1D7A7EFD-F727-4D1F-AC52-E9F1DED4F465Q36113248-B89940C5-9C0D-432F-90E4-E42767189349Q36372403-DE7D9626-13BE-42B7-91BA-A42C5943C7ACQ36631514-C7765272-7A84-493C-B7BC-B8B94B364184Q37255288-15FE83B4-2AA3-48FF-A6AB-CBC31349B864Q37366227-C7B7A387-CA56-471A-9769-4E93CDC39761Q37375636-87EBDA32-8A52-467C-AEE8-7E0CED80B289Q37621222-BFACF339-EB7D-441C-A0FF-AFBAF82063F6Q37693706-EF599961-5DF2-45CB-9809-F50CD28EFEE2Q37709507-D930342A-61C0-4E5E-90AF-73988A644759Q38460431-37B011CE-FDF3-4F80-A40E-68E9AE60DB81Q38991031-5D6E262C-A13B-4AF3-B72E-3D38E97B220BQ39147491-CE57752C-A064-4D86-88F2-888C19275D94Q41858523-4118FEE1-7EC3-498A-8064-B9D0D9DAAFE6Q43249156-A4F88B4C-8FF5-4A24-82AE-080241D1B94BQ45622203-E4DADAE5-88E7-41A9-A13E-8B75E3BD77CBQ46489215-188419E6-9516-4F0E-B6E0-DF8A22F0E061Q49399828-535CFD98-9D87-4D6D-ABFB-B0DAA1978218Q50995298-BD4E932F-3FD3-421F-80D9-F6A873C2341FQ52849107-9D2CE363-5013-4725-AF63-420288ED844CQ54559227-CA9D5549-BF33-4C10-9F4D-9B85444D8E85Q55036428-C296DAE7-E8FD-4BB1-AF10-CF15B7E38DF9Q57816466-B40392B1-F4C0-4B43-BD29-1BBCCAADF7B2Q58568604-BF41BE44-1D78-4B53-98FF-20F8E2B4D311
P2860
Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
@ast
Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
@en
Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
@nl
type
label
Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
@ast
Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
@en
Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
@nl
prefLabel
Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
@ast
Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
@en
Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
@nl
P2093
P356
P1433
P1476
Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
@en
P2093
P304
P356
10.1093/ANNONC/MDM538
P577
2007-11-23T00:00:00Z